Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin vs Heparin in STEMI PCI Post-Fibrinolysis
NCT06861374Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2025
- Primary completion
- Mar 2028
- Modality
- Peptides, Small Molecules
01
Overview
Randomised, open-label trial of bivalirudin in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Composite of all-cause death or BARC type 3, 5 bleeding at 30 days. Planned start May 2025; status: not yet recruiting.
02
Drugs
bivalirudin
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06861374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861374.